<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03096847</url>
  </required_header>
  <id_info>
    <org_study_id>CLEE011XDE01</org_study_id>
    <secondary_id>CLEE011XDE01</secondary_id>
    <secondary_id>2016-002556-24</secondary_id>
    <nct_id>NCT03096847</nct_id>
  </id_info>
  <brief_title>Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer</brief_title>
  <official_title>A National Phase IIIb, Multi-center, Open Label Study for Women and Men With Hormone-receptor Positive, HER-2 Negative Locally Advanced or Metastatic Breast Cancer Treated With Ribociclib (LEE011) in Combination With Letrozole</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a national, multi-center, open-label, phase IIIb trial to determine the efficacy and&#xD;
      safety of treatment with ribociclib (LEE011) plus letrozole in patients with HR+,&#xD;
      HER2-negative advanced (recurrent or metastatic) breast cancer. Patients were treated with&#xD;
      daily doses of 600 mg ribociclib (3-weeks-on/1-week-off schedule) in combination with 2.5 mg&#xD;
      letrozole daily (continuous dosing). Dose adjustments (dose reduction or interruption)&#xD;
      according to safety findings were allowed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main purpose of this study was to collect additional efficacy and safety data for the&#xD;
      combination of ribociclib and letrozole in a patient population broader than the MONALEESA-2&#xD;
      study (NCT01958021 / CLEE011A2301), and to provide access to ribociclib to patients for which&#xD;
      available treatment options are unsatisfactory treatment alternatives until the drug is&#xD;
      approved for this indication. Furthermore, this trial aimed to collect data for the&#xD;
      combination of ribociclib and letrozole in the context of current local routine therapy&#xD;
      algorithms for the treatment of metastatic and advanced breast cancer.&#xD;
&#xD;
      This multi-center, open-label, single-arm study aimed to evaluate the efficacy, safety, and&#xD;
      quality of life for the combination of ribociclib and letrozole in a patient population than&#xD;
      in the MONALEESA-2 study, i.e. in patients pretreated with one line of chemotherapy and/or a&#xD;
      maximum of two lines of endocrine therapy as well as premenopausal patients, without&#xD;
      limitations regarding the disease free interval after adjuvant therapy.&#xD;
&#xD;
      For ethical reasons no endocrine comparator drugs were investigated in this study. The&#xD;
      duration of study treatment of 80 weeks was adequate to determine the primary, secondary and&#xD;
      exploratory study parameters. The sample size was suitable to estimate the clinical benefit&#xD;
      rate (CBR) in this patient population with reasonable precision.&#xD;
&#xD;
      Goserelin was used in premenopausal patients, since it was shown that ovarian suppression of&#xD;
      estrogen release with luteinizing hormone-releasing hormone agonists (LHRHa) (such as&#xD;
      goserelin) is effective in preventing relapse in premenopausal women with early stage ER+&#xD;
      breast cancer (Klijn et al. 2001).&#xD;
&#xD;
      The efficacy and safety of ribociclib in combination with letrozole for the treatment of&#xD;
      postmenopausal women with advanced or metastatic breast cancer vs. placebo (i.e., letrozole&#xD;
      alone) was already demonstrated in the preceding, pivotal MONALESSA-2 study. Thus, for&#xD;
      ethical reasons no endocrine comparator drugs were investigated in the present RIBECCA study.&#xD;
&#xD;
      Generally, the single-arm, open-label design and the broadening of the study population&#xD;
      (compared to the pivotal MONALESSA-2 study) in the RIBECCA study was deemed appropriate to&#xD;
      further evaluate the efficacy and safety of ribociclib plus letrozole among breast cancer&#xD;
      patients in a treatment setting closer to routine care. The duration of study treatment of up&#xD;
      to 80 weeks was considered adequate to determine the primary, secondary and exploratory study&#xD;
      parameters. Moreover, the sample size was suitable to estimate the CBR in this patient&#xD;
      population with reasonable precision.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 24, 2016</start_date>
  <completion_date type="Actual">February 6, 2020</completion_date>
  <primary_completion_date type="Actual">December 11, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Benefit Rate (CBR) in Women and Men With Hormone Receptor Positiv, HER-2 Negative Breast Cancer Treated With Ribocilib and Letrozole</measure>
    <time_frame>At 24 weeks after last patient enrolled in trial</time_frame>
    <description>Clinical Benefit Rate (CBR) after 24 weeks of treatment as defined by RECIST 1.1 as percentage of patients with Complete Response (CR), Partial response (PR) or Stable disease (SD) lasting 24 weeks or longer as well as patients with Non-complete response, nonprogressive disease (NCRNPD).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) for Different Populations - Kaplan-Meier Estimates (%, 95% CI)</measure>
    <time_frame>At week 24 , week 48 and week 72</time_frame>
    <description>PFS based on radiologic assessment by investigator using RECIST 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) for Different Populations - Median Time to Progression or Death With 95% CI [Months]</measure>
    <time_frame>Up to approximately month 25</time_frame>
    <description>PFS based on radiologic assessment by investigator using RECIST 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) - Kaplan-Meier Estimates (%, 95% CI)</measure>
    <time_frame>At Week 24, Week 48 and Week 72</time_frame>
    <description>Overall survival (OS) defined as the time from date of start of treatment to date of death due to any cause. For the Kaplan-Meier estimates (%, 95% CI), the probability of survival at week 24, 48 and 72 is reported below.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) - Median Time to Progression or Death With 95% CI [Months]</measure>
    <time_frame>Up to approximatley 38 months</time_frame>
    <description>Overall survival (OS) defined as the time from date of start of treatment to date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) - Number of Censored Participants and Number of Deaths</measure>
    <time_frame>Up to approximatley 38 months</time_frame>
    <description>Overall survival (OS) defined as the time from date of start of treatment to date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR) - Kaplan-Meier Estimates (%, 95% CI)</measure>
    <time_frame>At week 24</time_frame>
    <description>Overall response rate (ORR) is the best overall response (BOR) of complete response (CR) or partial response (PR) as defined by RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline at Week 24 of Patient Reported Quality of Life (QoL) Via EORTC QLQ-C30</measure>
    <time_frame>Change from Baseline to Week 24</time_frame>
    <description>The QLQ-C30 is the core questionnaire of the EORTC QLQ, which has been developed for the assessment of the health-related QOL of cancer patients participating in international clinical trials. Using a linear transformation to standardize the raw scores, all scores finally range from 0 to 100, where a higher score represents a higher response level, e.g., a higher (&quot;better&quot;) level of functioning (applies to the first 6 items, items 1 to 6), but a higher (&quot;worse&quot;) level of symptoms (applies to the last 9 items, items 7 to 15). There is no aggregated total score, i.e., all scale scores were analyzed separately.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Quality of Life (QoL) Via EORTC BR-23 - Change From Baseline at Week 24 (Cycle 7)</measure>
    <time_frame>Baseline and Week 24 (Cycle 7)</time_frame>
    <description>To evaluate health related quality of life (QoL) via EORTC BR-23. The scoring approach for the QLQ-BR23 is identical in principle to that for the function and symptom scales / single items of the QLQ-C30, i.e., all scores finally range from 0 to 100, where a higher score represents a higher response level, e.g., a higher (&quot;better&quot;) level of functioning, (applies to the first 4 items, items 1 to 4) but a higher (&quot;worse&quot;) level of symptoms (applies to the last 4 items, items 5 to 8).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to 10% Deterioration in EORTC Global Health Status</measure>
    <time_frame>up to approximately 10 months</time_frame>
    <description>Time to 10% deterioration in the European Organisation for Research and Treatment of Cancer (EORTC) global health status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Events (TEAE)</measure>
    <time_frame>Up to Week 72</time_frame>
    <description>Adverse Events (AEs) were separated into TEAEs (defined as AEs occurring/worsening from first study drug treatment until 30 days after the last study drug treatment) and AEs in the pre-/post-treatment period.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">502</enrollment>
  <condition>Advanced Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>ribociclib + letrozole cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ribociclib + letrozole cohort A - postmenopausal women, or men; naïve.&#xD;
All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ribociclib + letrozole cohort B1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ribociclib + letrozole cohort B1 - premenopausal women or perimenopausal women; naïve&#xD;
All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.&#xD;
Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ribociclib + letrozole cohort B2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ribociclib + letrozole cohort B2 - premenopausal women or perimenopausal women or postmenopausal women, or men; pre-treated.&#xD;
All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.&#xD;
Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ribociclib</intervention_name>
    <description>All patients with oestrogen receptor positive advanced or metastatic breast cancer were treated with oral ribociclib at a dose of 600mg daily and oral letrozole 2.5mg daily. The study treatment for an individual patient began on Study Day 1 and continued until 80 weeks after the last patient enrolled the study or until disease progression, unacceptable toxicity, death or early discontinuation from the study for any other reason, whichever occured first.</description>
    <arm_group_label>ribociclib + letrozole cohort A</arm_group_label>
    <arm_group_label>ribociclib + letrozole cohort B1</arm_group_label>
    <arm_group_label>ribociclib + letrozole cohort B2</arm_group_label>
    <other_name>LEE011</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>letrozole</intervention_name>
    <description>All patients with oestrogen receptor positive advanced or metastatic breast cancer were treated with oral ribociclib at a dose of 600mg daily and oral letrozole 2.5mg daily. The study treatment for an individual patient began on Study Day 1 and continued until 80 weeks after the last patient enrolled the study or until disease progression, unacceptable toxicity, death or early discontinuation from the study for any other reason, whichever occured first.</description>
    <arm_group_label>ribociclib + letrozole cohort A</arm_group_label>
    <arm_group_label>ribociclib + letrozole cohort B1</arm_group_label>
    <arm_group_label>ribociclib + letrozole cohort B2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>goserelin</intervention_name>
    <description>Premenopausal patients additionally received goserelin 3.6mg as monthly implant</description>
    <arm_group_label>ribociclib + letrozole cohort A</arm_group_label>
    <arm_group_label>ribociclib + letrozole cohort B1</arm_group_label>
    <arm_group_label>ribociclib + letrozole cohort B2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient is an adult, ≥ 18 years old at the time of informed consent and has signed&#xD;
             informed consent before any trial related activities and according to local guidelines&#xD;
&#xD;
          -  Women and men with advanced (locoregionally recurrent or metastatic) breast cancer not&#xD;
             amenable to curative therapy.&#xD;
&#xD;
          -  Patient has a histologically and/or cytologically confirmed diagnosis of&#xD;
             estrogen-receptor positive and/or progesterone receptor positive and HER2-negative&#xD;
             breast cancer by local laboratory. Local pathology is sufficient for assessment.&#xD;
&#xD;
          -  Patient must have either:&#xD;
&#xD;
               1. Measurable disease, i.e., at least one measurable lesion as per RECIST 1.1&#xD;
                  criteria ).&#xD;
&#xD;
               2. Bone lesions: lytic or mixed (lytic + sclerotic) in the absence of measurable&#xD;
                  disease&#xD;
&#xD;
               3. Non-measurable disease&#xD;
&#xD;
          -  Patient has an Eastern Cooperative Oncology Group (ECOG) performance status ≤2&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Patient who received any CDK4/6 inhibitor or any mTOR inhibitor.&#xD;
&#xD;
          -  Patient has a known hypersensitivity to any of the excipients of ribociclib or&#xD;
             letrozole&#xD;
&#xD;
          -  Patients with current inflammatory breast cancer.&#xD;
&#xD;
          -  Patient has received &gt; 1 chemotherapy for the treatment of advanced/metastatic breast&#xD;
             cancer&#xD;
&#xD;
          -  Patient has received &gt; 2 endocrine therapies for the treatment of advanced/metastatic&#xD;
             breast cancer&#xD;
&#xD;
          -  Patient has central nervous system (CNS) involvement. If patient is fulfilling the&#xD;
             following 3 criteria she/he is eligible for the trial.&#xD;
&#xD;
               1. completed prior therapy (including radiation and/or surgery) for CNS metastases ≥&#xD;
                  28 days prior to the start of study and&#xD;
&#xD;
               2. CNS tumor is clinically stable at the time of screening and&#xD;
&#xD;
               3. Patient is not receiving steroids and enzyme inducing anti-epileptic medications&#xD;
                  for brain metastases&#xD;
&#xD;
          -  Patient has active cardiac disease or a history of cardiac dysfunction&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>80335</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Langen</city>
        <state>Hessen</state>
        <zip>63225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Recklinghausen</city>
        <state>North Rhine-westphalia</state>
        <zip>45657</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Luebeck</city>
        <state>Schleswig-holstein</state>
        <zip>23563</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Augsburg</city>
        <zip>86150</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10367</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10713</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10967</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13581</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>14195</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bielefeld</city>
        <zip>33604</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boeblingen</city>
        <zip>71032</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bonn</city>
        <zip>53111</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bottrop</city>
        <zip>46236</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chemnitz</city>
        <zip>09113</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dessau Rosslau</city>
        <zip>06847</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40479</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45136</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Esslingen</city>
        <zip>73730</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60398</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60431</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fuerstenwalde</city>
        <zip>15517</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fuerth</city>
        <zip>90766</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Georgsmarienhuette</city>
        <zip>49124</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Goettingen</city>
        <zip>37073</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Goslar</city>
        <zip>38642</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Greifswald</city>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22767</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <zip>30177</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <zip>30559</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hildesheim</city>
        <zip>31134</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jena</city>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kiel</city>
        <zip>24103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koeln</city>
        <zip>50935</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kulmbach</city>
        <zip>95326</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Landshut</city>
        <zip>84028</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leer</city>
        <zip>26789</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04277</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mannheim</city>
        <zip>68165</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marburg</city>
        <zip>35037</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Minden</city>
        <zip>32429</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moenchengladbach</city>
        <zip>41061</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenchen</city>
        <zip>80637</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenster</city>
        <zip>48145</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Neuruppin</city>
        <zip>16816</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nuernberg</city>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Offenbach</city>
        <zip>63069</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oldenburg</city>
        <zip>26121</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Passau</city>
        <zip>94032</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Potsdam</city>
        <zip>14467</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ravensburg</city>
        <zip>88214</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rotenburg</city>
        <zip>27356</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saarbruecken</city>
        <zip>66113</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Schweinfurt</city>
        <zip>97422</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stuttgart</city>
        <zip>70199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Suhl</city>
        <zip>98527</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Torgau</city>
        <zip>04860</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Trier</city>
        <zip>54290</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Troisdorf</city>
        <zip>53840</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Velbert</city>
        <zip>42551</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Voelklingen</city>
        <zip>66333</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Weinheim</city>
        <zip>69469</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wetzlar</city>
        <zip>35578</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65191</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wuerzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/ctrdweb/patientsummary/patientsummaries?patientSummaryId=729</url>
    <description>A Plain Language Trial Summary is available on novartisclinicaltrials.com</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 10, 2017</study_first_submitted>
  <study_first_submitted_qc>March 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2017</study_first_posted>
  <results_first_submitted>February 3, 2021</results_first_submitted>
  <results_first_submitted_qc>April 28, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 19, 2021</results_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ribociclib</keyword>
  <keyword>LEE011</keyword>
  <keyword>RIBECCA</keyword>
  <keyword>breast cancer</keyword>
  <keyword>breast carcinoma</keyword>
  <keyword>HR-positive</keyword>
  <keyword>HER2-negative</keyword>
  <keyword>advanced breast cancer</keyword>
  <keyword>Letrozole</keyword>
  <keyword>CDK4/6</keyword>
  <keyword>breast lump</keyword>
  <keyword>HER2 positive</keyword>
  <keyword>metastatic breast cancer</keyword>
  <keyword>breast cancer positive for human epidermal growth factor receptor 2 (HER2) HER2 positive metastatic breast cancer</keyword>
  <keyword>breast cancer progression</keyword>
  <keyword>estrogen-receptor (ER) positive(+) breast cancer</keyword>
  <keyword>Paget's disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Goserelin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data availability is according to the criteria and process described on https://www.clinicalstudydatarequest.com/.</ipd_description>
    <ipd_url>https://www.clinicalstudydatarequest.com/</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 5, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/47/NCT03096847/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 22, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/47/NCT03096847/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>504 participants were entered into the study, but 2 of these participants were not treated. The full analysis set is comprised of the 504 participants minus 17 participants, whose data were removed because of inspection findings, to equal 487 participants. This full analysis set includes the 2 participants who were entered into the study but were not treated.&#xD;
502 participants were treated; these 502 participants are included in the safety set.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ribociclib + Letrozole Cohort A</title>
          <description>postmenopausal women, or men; naïve.&#xD;
All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.</description>
        </group>
        <group group_id="P2">
          <title>Ribociclib + Letrozole Cohort B1</title>
          <description>premenopausal women or perimenopausal women; naïve&#xD;
All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.&#xD;
Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly</description>
        </group>
        <group group_id="P3">
          <title>Ribociclib + Letrozole Cohort B2</title>
          <description>premenopausal women or perimenopausal women or postmenopausal women, or men; pre-treated.&#xD;
All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.&#xD;
Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="319"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="157"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="307"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="154"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="100">Only the primary reason for disc. is included in this table.</participants>
                <participants group_id="P2" count="6">Only the primary reason for disc. is included in this table.</participants>
                <participants group_id="P3" count="19">Only the primary reason for disc. is included in this table.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="219"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="138"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="28"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive disease</title>
              <participants_list>
                <participants group_id="P1" count="97"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="78"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with study medication</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>New therapy for study indication</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ribociclib + Letrozole Cohort A</title>
          <description>postmenopausal women, or men; naïve.&#xD;
All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.</description>
        </group>
        <group group_id="B2">
          <title>Ribociclib + Letrozole Cohort B1</title>
          <description>premenopausal women or perimenopausal women; naïve&#xD;
All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.&#xD;
Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly</description>
        </group>
        <group group_id="B3">
          <title>Ribociclib + Letrozole Cohort B2</title>
          <description>premenopausal women or perimenopausal women or postmenopausal women, or men; pre-treated.&#xD;
All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.&#xD;
Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="319"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="157"/>
            <count group_id="B4" value="502"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="143"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="87"/>
                    <measurement group_id="B4" value="256"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="176"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="70"/>
                    <measurement group_id="B4" value="246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.7" spread="10.1"/>
                    <measurement group_id="B2" value="46.5" spread="4.9"/>
                    <measurement group_id="B3" value="62.8" spread="12.8"/>
                    <measurement group_id="B4" value="63.8" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="315"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="156"/>
                    <measurement group_id="B4" value="497"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="312"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="151"/>
                    <measurement group_id="B4" value="487"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Benefit Rate (CBR) in Women and Men With Hormone Receptor Positiv, HER-2 Negative Breast Cancer Treated With Ribocilib and Letrozole</title>
        <description>Clinical Benefit Rate (CBR) after 24 weeks of treatment as defined by RECIST 1.1 as percentage of patients with Complete Response (CR), Partial response (PR) or Stable disease (SD) lasting 24 weeks or longer as well as patients with Non-complete response, nonprogressive disease (NCRNPD).</description>
        <time_frame>At 24 weeks after last patient enrolled in trial</time_frame>
        <population>Full Analysis Set. Please note that the statistical significance test (test comparing groups) i.e., statistical analysis was not applicable for this outcome measure, since the primary objective was to assess the rate (per cohort) and not to compare two or more treatment arms, as this was a non-randomized, single arm open label trial.</population>
        <group_list>
          <group group_id="O1">
            <title>Ribociclib + Letrozole Cohort A</title>
            <description>postmenopausal women, or men; naïve.&#xD;
All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.</description>
          </group>
          <group group_id="O2">
            <title>Ribociclib + Letrozole Cohort B1</title>
            <description>premenopausal women or perimenopausal women; naïve All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily. Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly</description>
          </group>
          <group group_id="O3">
            <title>Ribociclib + Letrozole Cohort B2</title>
            <description>premenopausal women or perimenopausal women or postmenopausal women, or men; pre-treated. All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily. Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly</description>
          </group>
          <group group_id="O4">
            <title>Total</title>
            <description>Cohort A and Cohort B combined</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Benefit Rate (CBR) in Women and Men With Hormone Receptor Positiv, HER-2 Negative Breast Cancer Treated With Ribocilib and Letrozole</title>
          <description>Clinical Benefit Rate (CBR) after 24 weeks of treatment as defined by RECIST 1.1 as percentage of patients with Complete Response (CR), Partial response (PR) or Stable disease (SD) lasting 24 weeks or longer as well as patients with Non-complete response, nonprogressive disease (NCRNPD).</description>
          <population>Full Analysis Set. Please note that the statistical significance test (test comparing groups) i.e., statistical analysis was not applicable for this outcome measure, since the primary objective was to assess the rate (per cohort) and not to compare two or more treatment arms, as this was a non-randomized, single arm open label trial.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="307"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="154"/>
                <count group_id="O4" value="487"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CBR by week 24 (= BOR of CR or PR or SD or NCRNPD(Confirmed Best Overall Response (BOR))</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.2" lower_limit="57.5" upper_limit="68.6"/>
                    <measurement group_id="O2" value="57.7" lower_limit="36.9" upper_limit="76.6"/>
                    <measurement group_id="O3" value="56.5" lower_limit="48.3" upper_limit="64.5"/>
                    <measurement group_id="O4" value="60.8" lower_limit="56.3" upper_limit="65.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CBR by week 24 (= BOR of CR or PR or SD or NCRNPD (non-confirmed BOR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.7" lower_limit="66.3" upper_limit="76.6"/>
                    <measurement group_id="O2" value="69.2" lower_limit="48.2" upper_limit="85.7"/>
                    <measurement group_id="O3" value="64.3" lower_limit="56.2" upper_limit="71.8"/>
                    <measurement group_id="O4" value="69.2" lower_limit="64.9" upper_limit="73.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival (PFS) for Different Populations - Kaplan-Meier Estimates (%, 95% CI)</title>
        <description>PFS based on radiologic assessment by investigator using RECIST 1.1 criteria</description>
        <time_frame>At week 24 , week 48 and week 72</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Ribociclib + Letrozole Cohort A</title>
            <description>postmenopausal women, or men; naïve.&#xD;
All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.</description>
          </group>
          <group group_id="O2">
            <title>Ribociclib + Letrozole Cohort B1</title>
            <description>premenopausal women or perimenopausal women; naïve&#xD;
All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.&#xD;
Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly</description>
          </group>
          <group group_id="O3">
            <title>Ribociclib + Letrozole Cohort B2</title>
            <description>premenopausal women or perimenopausal women or postmenopausal women, or men; pre-treated.&#xD;
All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.&#xD;
Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS) for Different Populations - Kaplan-Meier Estimates (%, 95% CI)</title>
          <description>PFS based on radiologic assessment by investigator using RECIST 1.1 criteria</description>
          <population>Full Analysis Set</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="307"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Kaplan-Meier estimates (%, 95% CI) - Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.1" lower_limit="67.3" upper_limit="77.9"/>
                    <measurement group_id="O2" value="67.0" lower_limit="44.7" upper_limit="82.0"/>
                    <measurement group_id="O3" value="63.8" lower_limit="55.2" upper_limit="71.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kaplan-Meier estimates (%, 95% CI) - Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.9" lower_limit="55.7" upper_limit="67.5"/>
                    <measurement group_id="O2" value="58.7" lower_limit="36.8" upper_limit="75.2"/>
                    <measurement group_id="O3" value="47.5" lower_limit="38.7" upper_limit="55.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kaplan-Meier estimates (%, 95% CI) - week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.5" lower_limit="48.1" upper_limit="60.5"/>
                    <measurement group_id="O2" value="49.6" lower_limit="28.6" upper_limit="67.6"/>
                    <measurement group_id="O3" value="39.3" lower_limit="30.8" upper_limit="47.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival (PFS) for Different Populations - Median Time to Progression or Death With 95% CI [Months]</title>
        <description>PFS based on radiologic assessment by investigator using RECIST 1.1 criteria</description>
        <time_frame>Up to approximately month 25</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Ribociclib + Letrozole Cohort A</title>
            <description>postmenopausal women, or men; naïve.&#xD;
All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.</description>
          </group>
          <group group_id="O2">
            <title>Ribociclib + Letrozole Cohort B1</title>
            <description>premenopausal women or perimenopausal women; naïve&#xD;
All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.&#xD;
Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly</description>
          </group>
          <group group_id="O3">
            <title>Ribociclib + Letrozole Cohort B2</title>
            <description>premenopausal women or perimenopausal women or postmenopausal women, or men; pre-treated.&#xD;
All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.&#xD;
Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS) for Different Populations - Median Time to Progression or Death With 95% CI [Months]</title>
          <description>PFS based on radiologic assessment by investigator using RECIST 1.1 criteria</description>
          <population>Full Analysis Set</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="307"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.8" lower_limit="13.9" upper_limit="25.3"/>
                    <measurement group_id="O2" value="16.5" lower_limit="3.2" upper_limit="NA">The upper limit was not estimable. Existence of the confidence limits does not directly depend on the Kaplan-Meier curve itself (dropping below 0.75, 0.5 or 0.25), but on the curves that represent the confidence limits (CL) for the survivor function. They envelop the Kaplan-Meier curve.</measurement>
                    <measurement group_id="O3" value="8.8" lower_limit="8.1" upper_limit="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) - Kaplan-Meier Estimates (%, 95% CI)</title>
        <description>Overall survival (OS) defined as the time from date of start of treatment to date of death due to any cause. For the Kaplan-Meier estimates (%, 95% CI), the probability of survival at week 24, 48 and 72 is reported below.</description>
        <time_frame>At Week 24, Week 48 and Week 72</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Ribociclib + Letrozole Cohort A</title>
            <description>postmenopausal women, or men; naïve.&#xD;
All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.</description>
          </group>
          <group group_id="O2">
            <title>Ribociclib + Letrozole Cohort B1</title>
            <description>premenopausal women or perimenopausal women; naïve&#xD;
All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.&#xD;
Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly</description>
          </group>
          <group group_id="O3">
            <title>Ribociclib + Letrozole Cohort B2</title>
            <description>premenopausal women or perimenopausal women or postmenopausal women, or men; pre-treated.&#xD;
All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.&#xD;
Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) - Kaplan-Meier Estimates (%, 95% CI)</title>
          <description>Overall survival (OS) defined as the time from date of start of treatment to date of death due to any cause. For the Kaplan-Meier estimates (%, 95% CI), the probability of survival at week 24, 48 and 72 is reported below.</description>
          <population>Full Analysis Set</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="307"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Kaplan-Meier estimates (%, 95% CI) - Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.6" lower_limit="96.4" upper_limit="99.5"/>
                    <measurement group_id="O2" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O3" value="93.9" lower_limit="88.5" upper_limit="96.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kaplan-Meier estimates (%, 95% CI) - Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.3" lower_limit="89.7" upper_limit="95.7"/>
                    <measurement group_id="O2" value="87.5" lower_limit="66.1" upper_limit="95.8"/>
                    <measurement group_id="O3" value="86.1" lower_limit="79.2" upper_limit="90.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kaplan-Meier estimates (%, 95% CI) - Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.7" lower_limit="85.5" upper_limit="92.7"/>
                    <measurement group_id="O2" value="87.5" lower_limit="66.1" upper_limit="95.8"/>
                    <measurement group_id="O3" value="81.0" lower_limit="73.5" upper_limit="86.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) - Median Time to Progression or Death With 95% CI [Months]</title>
        <description>Overall survival (OS) defined as the time from date of start of treatment to date of death due to any cause.</description>
        <time_frame>Up to approximatley 38 months</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Ribociclib + Letrozole Cohort A</title>
            <description>postmenopausal women, or men; naïve.&#xD;
All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.</description>
          </group>
          <group group_id="O2">
            <title>Ribociclib + Letrozole Cohort B1</title>
            <description>premenopausal women or perimenopausal women; naïve&#xD;
All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.&#xD;
Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly</description>
          </group>
          <group group_id="O3">
            <title>Ribociclib + Letrozole Cohort B2</title>
            <description>premenopausal women or perimenopausal women or postmenopausal women, or men; pre-treated.&#xD;
All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.&#xD;
Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) - Median Time to Progression or Death With 95% CI [Months]</title>
          <description>Overall survival (OS) defined as the time from date of start of treatment to date of death due to any cause.</description>
          <population>Full Analysis Set</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="307"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Not estimable. Existence of the confidence limits does not directly depend on the Kaplan-Meier curve itself (dropping below 0.75, 0.5 or 0.25), but on the curves that represent the confidence limits (CL) for the survivor function. They envelop the Kaplan-Meier curve.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="30.9" upper_limit="NA">Not estimable. Existence of the confidence limits does not directly depend on the Kaplan-Meier curve itself (dropping below 0.75, 0.5 or 0.25), but on the curves that represent the confidence limits (CL) for the survivor function. They envelop the Kaplan-Meier curve.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="31.0" upper_limit="NA">Not estimable. Existence of the confidence limits does not directly depend on the Kaplan-Meier curve itself (dropping below 0.75, 0.5 or 0.25), but on the curves that represent the confidence limits (CL) for the survivor function. They envelop the Kaplan-Meier curve.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) - Number of Censored Participants and Number of Deaths</title>
        <description>Overall survival (OS) defined as the time from date of start of treatment to date of death due to any cause.</description>
        <time_frame>Up to approximatley 38 months</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Ribociclib + Letrozole Cohort A</title>
            <description>postmenopausal women, or men; naïve.&#xD;
All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.</description>
          </group>
          <group group_id="O2">
            <title>Ribociclib + Letrozole Cohort B1</title>
            <description>premenopausal women or perimenopausal women; naïve&#xD;
All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.&#xD;
Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly</description>
          </group>
          <group group_id="O3">
            <title>Ribociclib + Letrozole Cohort B2</title>
            <description>premenopausal women or perimenopausal women or postmenopausal women, or men; pre-treated.&#xD;
All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.&#xD;
Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) - Number of Censored Participants and Number of Deaths</title>
          <description>Overall survival (OS) defined as the time from date of start of treatment to date of death due to any cause.</description>
          <population>Full Analysis Set</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="307"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No. of censored (no death), n</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="240"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No. of events (deaths due to any cause), n</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate (ORR) - Kaplan-Meier Estimates (%, 95% CI)</title>
        <description>Overall response rate (ORR) is the best overall response (BOR) of complete response (CR) or partial response (PR) as defined by RECIST 1.1.</description>
        <time_frame>At week 24</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Ribociclib + Letrozole Cohort A</title>
            <description>postmenopausal women, or men; naïve.&#xD;
All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.</description>
          </group>
          <group group_id="O2">
            <title>Ribociclib + Letrozole Cohort B1</title>
            <description>premenopausal women or perimenopausal women; naïve&#xD;
All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.&#xD;
Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly</description>
          </group>
          <group group_id="O3">
            <title>Ribociclib + Letrozole Cohort B2</title>
            <description>premenopausal women or perimenopausal women or postmenopausal women, or men; pre-treated.&#xD;
All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.&#xD;
Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate (ORR) - Kaplan-Meier Estimates (%, 95% CI)</title>
          <description>Overall response rate (ORR) is the best overall response (BOR) of complete response (CR) or partial response (PR) as defined by RECIST 1.1.</description>
          <population>Full Analysis Set</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="307"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ORR by week 24 - (BOR of CR or PR) (confirmed)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.8" lower_limit="18.2" upper_limit="27.9"/>
                    <measurement group_id="O2" value="23.1" lower_limit="9.0" upper_limit="43.6"/>
                    <measurement group_id="O3" value="11.7" lower_limit="7.1" upper_limit="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ORR by week 24 - (BOR of CR or PR) (unconfirmed)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.8" lower_limit="20.0" upper_limit="30.0"/>
                    <measurement group_id="O2" value="30.8" lower_limit="14.3" upper_limit="51.8"/>
                    <measurement group_id="O3" value="16.2" lower_limit="10.8" upper_limit="23.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline at Week 24 of Patient Reported Quality of Life (QoL) Via EORTC QLQ-C30</title>
        <description>The QLQ-C30 is the core questionnaire of the EORTC QLQ, which has been developed for the assessment of the health-related QOL of cancer patients participating in international clinical trials. Using a linear transformation to standardize the raw scores, all scores finally range from 0 to 100, where a higher score represents a higher response level, e.g., a higher (&quot;better&quot;) level of functioning (applies to the first 6 items, items 1 to 6), but a higher (&quot;worse&quot;) level of symptoms (applies to the last 9 items, items 7 to 15). There is no aggregated total score, i.e., all scale scores were analyzed separately.</description>
        <time_frame>Change from Baseline to Week 24</time_frame>
        <population>Full Analysis Set. Included in the analysis are all patients with valid assessment at baseline and week 24. Some questions were conditional branching and thus did not apply to some participants. Also, some participants chose not to answer some questions / items; the responses were accepted as provided by the participants. Also, some participants discontinued during the course of the trial, and thus less measurements were taken at week 24 than at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Ribociclib + Letrozole Cohort A</title>
            <description>postmenopausal women, or men; naïve.&#xD;
All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.</description>
          </group>
          <group group_id="O2">
            <title>Ribociclib + Letrozole Cohort B1</title>
            <description>premenopausal women or perimenopausal women; naïve All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily. Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly</description>
          </group>
          <group group_id="O3">
            <title>Ribociclib + Letrozole Cohort B2</title>
            <description>premenopausal women or perimenopausal women or postmenopausal women, or men; pre-treated. All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily. Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly</description>
          </group>
          <group group_id="O4">
            <title>Ribociclib + Letrozole Cohort B</title>
            <description>premenopausal women or perimenopausal women or postmenopausal women, or men; naïve + pre-treated&#xD;
All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o.daily.&#xD;
Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at Week 24 of Patient Reported Quality of Life (QoL) Via EORTC QLQ-C30</title>
          <description>The QLQ-C30 is the core questionnaire of the EORTC QLQ, which has been developed for the assessment of the health-related QOL of cancer patients participating in international clinical trials. Using a linear transformation to standardize the raw scores, all scores finally range from 0 to 100, where a higher score represents a higher response level, e.g., a higher (&quot;better&quot;) level of functioning (applies to the first 6 items, items 1 to 6), but a higher (&quot;worse&quot;) level of symptoms (applies to the last 9 items, items 7 to 15). There is no aggregated total score, i.e., all scale scores were analyzed separately.</description>
          <population>Full Analysis Set. Included in the analysis are all patients with valid assessment at baseline and week 24. Some questions were conditional branching and thus did not apply to some participants. Also, some participants chose not to answer some questions / items; the responses were accepted as provided by the participants. Also, some participants discontinued during the course of the trial, and thus less measurements were taken at week 24 than at baseline.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="307"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="154"/>
                <count group_id="O4" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Global health status - Change from baseline to Week 24 (C7D1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="181"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="75"/>
                    <count group_id="O4" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" spread="23.7"/>
                    <measurement group_id="O2" value="11.7" spread="20.8"/>
                    <measurement group_id="O3" value="5.0" spread="26.2"/>
                    <measurement group_id="O4" value="6.1" spread="25.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Functioning - Change from baseline to Week 24 (C7D1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="183"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="75"/>
                    <count group_id="O4" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" spread="19.9"/>
                    <measurement group_id="O2" value="-3.6" spread="10.7"/>
                    <measurement group_id="O3" value="-2.2" spread="17.7"/>
                    <measurement group_id="O4" value="-2.4" spread="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Functioning - Change from baseline to Week 24 (C7D1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="182"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="75"/>
                    <count group_id="O4" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.6" spread="31.9"/>
                    <measurement group_id="O2" value="-17" spread="21.8"/>
                    <measurement group_id="O3" value="-1.3" spread="34.7"/>
                    <measurement group_id="O4" value="-3.9" spread="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional Functioning - Change from baseline to Week 24 (C7D1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="182"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="75"/>
                    <count group_id="O4" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.6" spread="24.2"/>
                    <measurement group_id="O2" value="-9.4" spread="25.0"/>
                    <measurement group_id="O3" value="-3.6" spread="21.8"/>
                    <measurement group_id="O4" value="-4.6" spread="22.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cognitive Functioning - Change from baseline to Week 24 (C7D1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="182"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="75"/>
                    <count group_id="O4" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="23.7"/>
                    <measurement group_id="O2" value="2.2" spread="28.1"/>
                    <measurement group_id="O3" value="1.1" spread="21.6"/>
                    <measurement group_id="O4" value="1.3" spread="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Functioning - Change from baseline to Week 24 (C7D1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="181"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="75"/>
                    <count group_id="O4" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.9" spread="27.9"/>
                    <measurement group_id="O2" value="-16" spread="21.3"/>
                    <measurement group_id="O3" value="-5.3" spread="31.3"/>
                    <measurement group_id="O4" value="-7.0" spread="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue - Change from baseline to Week 24 (C7D1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="182"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="75"/>
                    <count group_id="O4" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="25.9"/>
                    <measurement group_id="O2" value="11.1" spread="20.6"/>
                    <measurement group_id="O3" value="3.9" spread="27.1"/>
                    <measurement group_id="O4" value="5.1" spread="26.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea / Vomiting - Change from baseline to Week 24 (C7D1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="182"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="75"/>
                    <count group_id="O4" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="16.7"/>
                    <measurement group_id="O2" value="1.1" spread="22.2"/>
                    <measurement group_id="O3" value="-4.9" spread="19.1"/>
                    <measurement group_id="O4" value="-3.9" spread="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain - Change from baseline to Week 24 (C7D1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="182"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2" spread="31.9"/>
                    <measurement group_id="O2" value="15.6" spread="24.8"/>
                    <measurement group_id="O3" value="9.0" spread="27.6"/>
                    <measurement group_id="O4" value="10.1" spread="27.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnoea - Change from baseline to Week 24 (C7D1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="182"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="75"/>
                    <count group_id="O4" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="32.4"/>
                    <measurement group_id="O2" value="4.4" spread="21.3"/>
                    <measurement group_id="O3" value="-5.3" spread="30.5"/>
                    <measurement group_id="O4" value="-3.7" spread="29.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia - Change from baseline to Week 24 (C7D1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="183"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="75"/>
                    <count group_id="O4" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="33.2"/>
                    <measurement group_id="O2" value="6.7" spread="31.4"/>
                    <measurement group_id="O3" value="4.9" spread="32.7"/>
                    <measurement group_id="O4" value="5.2" spread="32.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appetite loss - Change from baseline to Week 24 (C7D1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="181"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2" spread="33.7"/>
                    <measurement group_id="O2" value="6.7" spread="28.7"/>
                    <measurement group_id="O3" value="1.4" spread="30.9"/>
                    <measurement group_id="O4" value="2.2" spread="30.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation - Change from baseline to Week 24 (C7D1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="183"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7" spread="26.6"/>
                    <measurement group_id="O2" value="2.2" spread="26.6"/>
                    <measurement group_id="O3" value="-3.6" spread="27.9"/>
                    <measurement group_id="O4" value="-2.6" spread="27.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea - Change from baseline to Week 24 (C7D1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="182"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="24.6"/>
                    <measurement group_id="O2" value="0.0" spread="45.4"/>
                    <measurement group_id="O3" value="2.3" spread="27.2"/>
                    <measurement group_id="O4" value="1.9" spread="30.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Financial Problems - Change from baseline to Week 24 (C7D1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="179"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="27.7"/>
                    <measurement group_id="O2" value="-4.4" spread="24.8"/>
                    <measurement group_id="O3" value="-1.4" spread="25.1"/>
                    <measurement group_id="O4" value="-1.9" spread="24.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Reported Quality of Life (QoL) Via EORTC BR-23 - Change From Baseline at Week 24 (Cycle 7)</title>
        <description>To evaluate health related quality of life (QoL) via EORTC BR-23. The scoring approach for the QLQ-BR23 is identical in principle to that for the function and symptom scales / single items of the QLQ-C30, i.e., all scores finally range from 0 to 100, where a higher score represents a higher response level, e.g., a higher (&quot;better&quot;) level of functioning, (applies to the first 4 items, items 1 to 4) but a higher (&quot;worse&quot;) level of symptoms (applies to the last 4 items, items 5 to 8).</description>
        <time_frame>Baseline and Week 24 (Cycle 7)</time_frame>
        <population>Full Analysis Set. Included in the analysis are all patients with valid assessment at baseline and week 24. Some questions were conditional branching and thus did not apply to some participants. Also, some participants chose not to answer some questions / items; the responses were accepted as provided by the participants. Also, some participants discontinued during the course of the trial, and thus less measurements were taken at week 24 than at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Ribociclib + Letrozole Cohort A</title>
            <description>postmenopausal women, or men; naïve.&#xD;
All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.</description>
          </group>
          <group group_id="O2">
            <title>Ribociclib + Letrozole Cohort B1</title>
            <description>premenopausal women or perimenopausal women; naïve All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily. Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly</description>
          </group>
          <group group_id="O3">
            <title>Ribociclib + Letrozole Cohort B2</title>
            <description>premenopausal women or perimenopausal women or postmenopausal women, or men; pre-treated. All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily. Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly</description>
          </group>
          <group group_id="O4">
            <title>Ribociclib + Letrozole Cohort B</title>
            <description>premenopausal women or perimenopausal women or postmenopausal women, or men; naïve + pre-treated&#xD;
All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o.daily.&#xD;
Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Reported Quality of Life (QoL) Via EORTC BR-23 - Change From Baseline at Week 24 (Cycle 7)</title>
          <description>To evaluate health related quality of life (QoL) via EORTC BR-23. The scoring approach for the QLQ-BR23 is identical in principle to that for the function and symptom scales / single items of the QLQ-C30, i.e., all scores finally range from 0 to 100, where a higher score represents a higher response level, e.g., a higher (&quot;better&quot;) level of functioning, (applies to the first 4 items, items 1 to 4) but a higher (&quot;worse&quot;) level of symptoms (applies to the last 4 items, items 5 to 8).</description>
          <population>Full Analysis Set. Included in the analysis are all patients with valid assessment at baseline and week 24. Some questions were conditional branching and thus did not apply to some participants. Also, some participants chose not to answer some questions / items; the responses were accepted as provided by the participants. Also, some participants discontinued during the course of the trial, and thus less measurements were taken at week 24 than at baseline.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="307"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="154"/>
                <count group_id="O4" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>EORTC QLQ-BR23 BODY IMAGE during the study - change from baseline at cycle 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="167"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="72"/>
                    <count group_id="O4" value="87"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="18.2"/>
                    <measurement group_id="O2" value="-0.6" spread="22.2"/>
                    <measurement group_id="O3" value="0.4" spread="22.7"/>
                    <measurement group_id="O4" value="0.2" spread="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EORTC QLQ-BR23 SEXUAL FUNCTIONING during the study - change from baseline at cycle 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="120"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="17.7"/>
                    <measurement group_id="O2" value="0.0" spread="24.5"/>
                    <measurement group_id="O3" value="0.8" spread="18.0"/>
                    <measurement group_id="O4" value="0.7" spread="19.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EORTC QLQ-BR23 SEXUAL ENJOYMENT during the study - change from baseline at cycle 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="31.3"/>
                    <measurement group_id="O2" value="-17" spread="23.6"/>
                    <measurement group_id="O3" value="7.4" spread="26.9"/>
                    <measurement group_id="O4" value="5.0" spread="27.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EORTC QLQ-BR23 FUTURE PERSPECTIVE during the study - change from baseline at cycle 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="172"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20" spread="33.4"/>
                    <measurement group_id="O2" value="-24" spread="26.6"/>
                    <measurement group_id="O3" value="-12" spread="26.2"/>
                    <measurement group_id="O4" value="-14" spread="26.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EORTC QLQ-BR23 SYSTEMATIC THERAPY during the study - change from baseline at cycle 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="180"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.4" spread="16.6"/>
                    <measurement group_id="O2" value="-13" spread="22.3"/>
                    <measurement group_id="O3" value="-6.0" spread="14.9"/>
                    <measurement group_id="O4" value="-7.1" spread="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EORTC QLQ-BR23 BREAST SYMPTOMS during the study - change from baseline at cycle 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="172"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="15.7"/>
                    <measurement group_id="O2" value="8.3" spread="22.7"/>
                    <measurement group_id="O3" value="0.9" spread="17.5"/>
                    <measurement group_id="O4" value="2.2" spread="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EORTC QLQ-BR23 ARM SYMPTOMS during the study - change from baseline at cycle 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="175"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="21.1"/>
                    <measurement group_id="O2" value="-1.5" spread="22.6"/>
                    <measurement group_id="O3" value="-2.1" spread="18.1"/>
                    <measurement group_id="O4" value="-2.0" spread="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EORTC QLQ-BR23 HAIR LOSS during the study - change from baseline at cycle 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22" spread="43.4"/>
                    <measurement group_id="O2" value="-17" spread="23.6"/>
                    <measurement group_id="O3" value="-14" spread="33.9"/>
                    <measurement group_id="O4" value="-15" spread="32.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to 10% Deterioration in EORTC Global Health Status</title>
        <description>Time to 10% deterioration in the European Organisation for Research and Treatment of Cancer (EORTC) global health status</description>
        <time_frame>up to approximately 10 months</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Ribociclib + Letrozole Cohort A</title>
            <description>postmenopausal women, or men; naïve.&#xD;
All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.</description>
          </group>
          <group group_id="O2">
            <title>Ribociclib + Letrozole Cohort B1</title>
            <description>premenopausal women or perimenopausal women; naïve&#xD;
All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.&#xD;
Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly</description>
          </group>
          <group group_id="O3">
            <title>Ribociclib + Letrozole Cohort B2</title>
            <description>premenopausal women or perimenopausal women or postmenopausal women, or men; pre-treated.&#xD;
All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.&#xD;
Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly</description>
          </group>
          <group group_id="O4">
            <title>Total</title>
            <description>Cohorts A, B1 and B2 combined</description>
          </group>
        </group_list>
        <measure>
          <title>Time to 10% Deterioration in EORTC Global Health Status</title>
          <description>Time to 10% deterioration in the European Organisation for Research and Treatment of Cancer (EORTC) global health status</description>
          <population>Full Analysis Set</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="307"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="154"/>
                <count group_id="O4" value="487"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" lower_limit="2.8" upper_limit="4.6"/>
                    <measurement group_id="O2" value="3.7" lower_limit="1.8" upper_limit="10.1"/>
                    <measurement group_id="O3" value="2.8" lower_limit="1.8" upper_limit="4.6"/>
                    <measurement group_id="O4" value="3.0" lower_limit="2.8" upper_limit="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment Emergent Adverse Events (TEAE)</title>
        <description>Adverse Events (AEs) were separated into TEAEs (defined as AEs occurring/worsening from first study drug treatment until 30 days after the last study drug treatment) and AEs in the pre-/post-treatment period.</description>
        <time_frame>Up to Week 72</time_frame>
        <population>Safety Set</population>
        <group_list>
          <group group_id="O1">
            <title>Ribociclib + Letrozole Cohort A</title>
            <description>postmenopausal women, or men; naïve.&#xD;
All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.</description>
          </group>
          <group group_id="O2">
            <title>Ribociclib + Letrozole Cohort B1</title>
            <description>premenopausal women or perimenopausal women; naïve&#xD;
All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.&#xD;
Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly</description>
          </group>
          <group group_id="O3">
            <title>Ribociclib + Letrozole Cohort B2</title>
            <description>premenopausal women or perimenopausal women or postmenopausal women, or men; pre-treated.&#xD;
All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.&#xD;
Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Emergent Adverse Events (TEAE)</title>
          <description>Adverse Events (AEs) were separated into TEAEs (defined as AEs occurring/worsening from first study drug treatment until 30 days after the last study drug treatment) and AEs in the pre-/post-treatment period.</description>
          <population>Safety Set</population>
          <units>Number of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="319"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total AEs (i.e., Includes any type of AE.)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="318"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-serious AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="317"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs with suspected relationship to ribociclib</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="302"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to discontinuation of ribociclib</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs with fatal outcome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>All Collected Deaths</title>
        <description>On treatment deaths were collected from FPFT up to 30 days after study drug discontinuation, for a maximum duration of 1150 days (approx 3.15 years). (Treatment duration ranged from 2 days to 1120 days). Deaths post treatment survival follow up were collected after the on- treatment period, up to approx. 3.15 years. Patients who didn't die during the on-treatment period and had not stopped study participation at the time of data cut-off (end of study) were censored.</description>
        <time_frame>on-treatment deaths: up to approx 3.15 years; all deaths: approx 3.15 years</time_frame>
        <population>Clinical database population - all treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Ribociclib + Letrozole Cohort A</title>
            <description>postmenopausal women, or men; naïve.&#xD;
All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.</description>
          </group>
          <group group_id="O2">
            <title>Ribociclib + Letrozole Cohort B1</title>
            <description>premenopausal women or perimenopausal women; naïve All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily. Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly</description>
          </group>
          <group group_id="O3">
            <title>Ribociclib + Letrozole Cohort B2</title>
            <description>premenopausal women or perimenopausal women or postmenopausal women, or men; pre-treated. All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily. Premenopausal patients additionally rec</description>
          </group>
          <group group_id="O4">
            <title>Total</title>
            <description>Cohort A and Cohort B combined</description>
          </group>
        </group_list>
        <measure>
          <title>All Collected Deaths</title>
          <description>On treatment deaths were collected from FPFT up to 30 days after study drug discontinuation, for a maximum duration of 1150 days (approx 3.15 years). (Treatment duration ranged from 2 days to 1120 days). Deaths post treatment survival follow up were collected after the on- treatment period, up to approx. 3.15 years. Patients who didn't die during the on-treatment period and had not stopped study participation at the time of data cut-off (end of study) were censored.</description>
          <population>Clinical database population - all treated participants</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="319"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="157"/>
                <count group_id="O4" value="502"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>on-treatment deaths</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="319"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="157"/>
                    <count group_id="O4" value="502"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total deaths</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="307"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="154"/>
                    <count group_id="O4" value="487"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="60"/>
                    <measurement group_id="O4" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days, up to a maximum duration of 1150 days (approx. 3.15 years).(Treatment duration ranged from 2 days to 1120 days.)</time_frame>
      <desc>For this study, disease progression was NOT classified as an Adverse Event.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ribociclib + Letrozole Cohort A</title>
          <description>postmenopausal women, or men; naïve.&#xD;
All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.</description>
        </group>
        <group group_id="E2">
          <title>Ribociclib + Letrozole Cohort B</title>
          <description>premenopausal women or perimenopausal women or postmenopausal women, or men; naïve + pre-treated&#xD;
All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o.daily.&#xD;
Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly</description>
        </group>
        <group group_id="E3">
          <title>Ribociclib + Letrozole Cohort B1</title>
          <description>premenopausal women or perimenopausal women; naïve&#xD;
All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.&#xD;
Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly</description>
        </group>
        <group group_id="E4">
          <title>Ribociclib + Letrozole Cohort B2</title>
          <description>premenopausal women or perimenopausal women or postmenopausal women, or men; pre-treated.&#xD;
All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.&#xD;
Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly</description>
        </group>
        <group group_id="E5">
          <title>Total</title>
          <description>Total</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (22.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="97" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="45" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="147" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>DISSEMINATED INTRAVASCULAR COAGULATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>FEBRILE NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>HYPERFIBRINOLYSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>PANCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>BRADYARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>CARDIAC ARREST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>SUPRAVENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTHYROIDISM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN LOWER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>ANAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>ILEUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>INTESTINAL STRANGULATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>COMPLICATION OF DEVICE INSERTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>DEATH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>GENERAL PHYSICAL HEALTH DETERIORATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>IMPAIRED HEALING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>BILE DUCT STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>BILIARY COLIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>DRUG-INDUCED LIVER INJURY</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>HEPATIC CIRRHOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>HEPATOTOXICITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>JAUNDICE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>ABSCESS JAW</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>ATYPICAL PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS INFECTIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>CYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>CYSTITIS ESCHERICHIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>DEVICE RELATED INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>DIVERTICULITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>EMPHYSEMATOUS CHOLECYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>ERYSIPELAS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>FEBRILE INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>HELICOBACTER GASTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>INFECTIOUS PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>MASTITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>PROTEUS INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>RESPIRATORY SYNCYTIAL VIRUS INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>UROSEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>ANKLE FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>CERVICAL VERTEBRAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>FEMORAL NECK FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>FEMUR FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>HIP FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>HUMERUS FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>INCISIONAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>JAW FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>POST-TRAUMATIC PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE ADHESION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>PROCEDURAL COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>RADIUS FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>RIB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>TIBIA FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>UPPER LIMB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>ASPARTATE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>BLOOD BILIRUBIN INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>C-REACTIVE PROTEIN INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>HAEMOGLOBIN DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>NEUTROPHIL COUNT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>WHITE BLOOD CELL COUNT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>HYPERCALCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>HYPERKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>HYPONATRAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>HYPOPHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>TUMOUR LYSIS SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>BONE LESION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>BONE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>FLANK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>LUMBAR SPINAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>MOBILITY DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>OSTEITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>OSTEONECROSIS OF JAW</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>SPINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>BRONCHIAL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>CANCER PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>COLON CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>MALIGNANT PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>METASTASES TO BONE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>METASTASES TO SPINE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>RENAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA OF THE TONGUE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>TUMOUR PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CEREBRAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>MONOPLEGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>NEUROPATHY PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>PARAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>PERIPHERAL NERVE LESION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>DEVICE LOOSENING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>PANIC ATTACK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>SOMATIC SYMPTOM DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE KIDNEY INJURY</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>HAEMATURIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>KIDNEY CONGESTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>RENAL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>RENAL IMPAIRMENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>URETERIC STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>URETEROLITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>URINARY INCONTINENCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>URINARY RETENTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>URINARY TRACT OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>PELVIC PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>DYSPNOEA EXERTIONAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>HYPERVENTILATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>PNEUMONITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>PULMONARY FIBROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>SKIN ULCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>CIRCULATORY COLLAPSE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE CRISIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (22.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="315" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="181" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="156" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="496" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="82" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="115" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>LYMPHOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="162" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="88" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="73" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="250" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="44" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>VERTIGO</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="50" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>DRY EYE</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="33" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>LACRIMATION INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="45" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="29" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="46" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="94" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="125" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>DRY MOUTH</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="38" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="39" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="130" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="68" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="207" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>STOMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="60" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>TOOTHACHE</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="97" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="123" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="59" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="197" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="57" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="37" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>SEASONAL ALLERGY</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="24" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>CYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="30" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="143" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="48" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ARTHROPOD BITE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>ARTHROPOD STING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="111" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>ASPARTATE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="102" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>BLOOD BILIRUBIN INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>BLOOD CREATININE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="39" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>BLOOD LACTATE DEHYDROGENASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>BLOOD THYROID STIMULATING HORMONE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>ELECTROCARDIOGRAM QT PROLONGED</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="37" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>GAMMA-GLUTAMYLTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="51" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>NEUTROPHIL COUNT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="65" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>WEIGHT INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>WHITE BLOOD CELL COUNT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="45" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="63" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>HYPERKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>HYPOCALCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="96" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="61" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>BONE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="50" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="35" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="24" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="75" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="38" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>DYSGEUSIA</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="31" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="92" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>HYPOAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>POLYNEUROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="57" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>SLEEP DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="23" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>VULVOVAGINAL DRYNESS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="75" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="74" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" subjects_affected="119" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="52" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="176" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>DRY SKIN</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="39" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="63" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="66" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HOT FLUSH</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="74" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="47" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>+ 1 862 778 8300</phone>
      <email>Novartis.email@Novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

